RCM
BLUE

Riverhead Capital Management’s bluebird bio BLUE Stock Holding History

Riverhead Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20
Closed -$37K – 1496
2018
Q3 		$37K Sell
20
-3
-13% -$6.2K ﹤0.01% 1512
2018
Q2 		$47K Sell
23
-8
-26% -$18.2K ﹤0.01% 1468
2018
Q1 		$68K Hold
31
– – ﹤0.01% 1421
2017
Q4 		$71K Buy
+31
New +$62.9K ﹤0.01% 1423

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverhead Capital Management's BLUE Position: Q4 2018 in Review

Riverhead Capital Management sold out of bluebird bio (BLUE) in Q4 2018, closing a stake of 20 shares — an estimated $37K sold.

Riverhead Capital Management first reported a position in BLUE in Q4 2017 and held it in 4 quarters. The position peaked at $71K in Q4 2017. 251 funds tracked by Wall St. Rank hold BLUE as of Q4 2018.

  • Riverhead Capital Management reported no remaining bluebird bio position as of Q4 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 20 bluebird bio shares in Q4 2018, an estimated $37K.
  • Riverhead Capital Management first reported a position in bluebird bio in Q4 2017 and held it in 4 quarters.
  • Riverhead Capital Management's bluebird bio position peaked at $71K in Q4 2017.
  • 251 funds tracked by Wall St. Rank held bluebird bio as of Q4 2018.

Based on Riverhead Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.